News

Soliris (eculizumab) is safe and effective for treating children with various types of hemolytic uremic syndrome (HUS), including atypical HUS (aHUS), according to a real-world study involving pediatric patients in Israel. In fact, more than half of the children with aHUS given Soliris in the study achieved a…

Plasma exchange therapy successfully managed atypical hemolytic uremic syndrome (aHUS) triggered by pancreas inflammation in a 72-year-old man, according to a case report from China. However, discontinuation of plasma exchange and a transition to hemodialysis — a treatment used to remove waste and excessive fluid from the blood when…

Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS) in a boy in China. The case was described in the report, “Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients:…

Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement from Samsung Bioepis and Teva Pharmaceuticals. The biosimilar is authorized to treat people with atypical hemolytic uremic syndrome (aHUS), as well as paroxysmal nocturnal hemoglobinuria, and…

A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not suspected of having the rare condition until five days after her baby’s birth, which resulted in her not receiving the correct treatment, according to a case report from researchers in…

COVID-19 was the likely trigger of atypical hemolytic uremic syndrome (aHUS) in a boy found to carry a mutation that reduced the levels of an immune protein called CD46, which may have increased his chance of developing the disease, according to a report from Iran. The boy first improved…

Atypical hemolytic uremic syndrome (aHUS) can be a rare complication of a procedure to remove gallstones, according to a report in the U.S. that describes the case of a teenage girl who developed the condition secondary to post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. The study, “Atypical hemolytic…

Early plasma exchange therapy followed by Ultomiris  (ravulizumab) treatment successfully managed atypical hemolytic uremic syndrome (aHUS) in an 83-year-old woman, according to a report from Japan. The woman started showing symptoms of aHUS after a bone fracture. Genetic testing revealed she had a mutation in the CFI gene,…

The pregnancy-related complication HELLP syndrome — fully known as hemolysis, elevated liver enzymes, and low platelets syndrome, which causes high blood pressure and organ damage — is sometimes confused with atypical hemolytic uremic syndrome, or aHUS, a rare disease in which kidney dysfunction persists for a long time, especially…

Soliris (eculizumab) largely reduces the risk of long-term kidney problems in women who develop atypical hemolytic uremic syndrome (aHUS) during or after pregnancy, a meta-analysis study has found. “This analysis highlights the severe kidney and pregnancy outcomes associated with [pregnancy-associated aHUS],” researchers wrote, noting Soliris treatment is beneficial…